| Authors: |
Cecchini M; Department of Internal Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT, USA. Electronic address: michael.cecchini@yale.edu., Cruz-Correa M; University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico, and Pan-American Center for Oncology Trials, San Juan, Puerto Rico., Han SW; Department of Internal Medicine, Seoul National University Hospital and Seoul National University Cancer Research Institute, Seoul, Republic of Korea., Raghav K; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Landa-Magdalena A; Department of Medical Oncology, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain., Strickler JH; Department of Medicine, Duke University, Durham, NC, USA., Calvo A; Gregorio Marañón University General Hospital, Madrid, Spain., Hollebecque A; Gustave Roussy, Villejuif, France., Nakajima TE; Kyoto University Graduate School of Medicine, Kyoto, Japan., Perl G; Thoracic Cancer Service, Davidoff Cancer Center, Beilinson, Petah Tikva, Israel., Jain V; Mater Hospital Brisbane, Queensland, Australia., Hunter Z; AbbVie Inc, North Chicago, IL, USA., Chan EM; AbbVie Inc, North Chicago, IL, USA., Blaney M; AbbVie Inc, North Chicago, IL, USA., Li R; AbbVie Inc, North Chicago, IL, USA., Vasilopoulos A; AbbVie Inc, North Chicago, IL, USA., Parikh A; AbbVie Inc, North Chicago, IL, USA., Sharma MR; START Center for Cancer Research - Midwest, Grand Rapids, MI, USA. |
